Despite the varied effects of galectin-3 up- or downregulation in the mouse models described above, PSC patients displayed higher serum and urinary galectin-3 levels than IBD patients [148], suggesting that monitoring of galectin-3 amounts may be helpful for the early diagnosis of PSC in patients with IBD. This evidence concerns the gene LGALS3 and inflammatory bowel disease.